Background and objectives Selection of the first-dose-inneonates is challenging. The objective of this proof-ofconcept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. Methods We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice and adults to develop population pharmacokinetic models using NONMEM. We also develop a physiologically-based pharmacokinetic model from in vitro-in silico data using Simcyp. These three models were then used to predict neonatal pharmacokinetics and dosing regimens for fluconazole.
Conclusion A model-based bridging approach provided consistent predictions of fluconazole pharmacokinetic parameters in neonates and demonstrated the feasibility of this approach to justify the first-dose-in-neonates, based on all data available from different sources (including physiological informations, preclinical studies and adult data), allowing evidence-based decisions of neonatal dose rather than empiricism.
Key Points
Model-based extrapolations from juvenile mice, adults and in vitro-in silico data provided consistent predictions of pharmacokinetics of fluconazole in neonates. Our data strongly support the use of different sources of pharmacokinetic information to predict the initial dosage in neonates Dose bridging studies support the rational of first dose in neonates. Despite difficulties, such bridging approaches should be further tested and validated, as it looks being the only way to select the first dose in neonates using a scientific ''evidence based'' approach Knowledge of developmental Pharmacology is indispensable to predict dose in neonates
Introduction
Pharmacological research in neonates is an important component of drug development programs [1] . The overall goal is the determination of safe and effective regimens for neonates. The introduction of the Paediatric Regulation by the European Union, together with the renewal of the Pediatric Rule by the US Food and Drug Administration on the requirements for pediatric labeling made it mandatory for sponsors to develop drugs for the pediatric population, focusing on a rational dosage selection in pediatric clinical trials [2, 3] . Neonatal drug evaluations present many challenges that are related to rapid physiological changes during early life as well as a myriad of ethical and practical obstacles to clinical research [4] . The selection of the firstdose to be given to neonates is a major challenge that should be based on the optimal use of all available data rather than a ''trial and error method'' that is associated with potential risks of inefficacy and/or toxicity.
Neonates cannot be included in dose escalation studies similar to those conducted in adults or older children. Therefore, in order to optimize dosage selection in neonatal clinical trials, extrapolation methodologies based on already available data should be promoted [5] . A valuable approach is pharmacokinetic bridging, which involves dose selection and adjustment in the target population based on known pharmacokinetic differences with a ''reference'' population [6] .
We selected fluconazole as a model compound to conduct a proof-of-concept ''bridging study''. Fluconazole has been used for many years to prevent or treat neonatal candidiasis in an off-label manner [7, 8] . Following regulatory guidelines from both the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) [9] [10] [11] , fluconazole is a good candidate for pharmacokinetic bridging studies because (1) pharmacokineticpharmacodynamic relationship can be assumed to be similar across all age groups including neonates, and (2) fluconazole is primarily eliminated by the kidney. The knowledge of developmental pharmacology (i.e. renal maturation) is indispensable to interpret developmental pharmacokinetics of fluconazole. Published data clearly show that pharmacokinetic parameters are highly dependent on age with major changes during the neonatal period [12, 13] . Our objective was to evaluate if selection of the first-dose-in-neonates using a pharmacokinetic modelbased bridging approach is possible and accurate, when based on available data from difference sources of studies (preclinical studies, adult pharmacokinetic data, and in vitro-in silico data), along with knowledge of physiological changes and developmental pharmacokinetics.
Methods
Four sets of data were available to perform the bridging study (Table 1) : juvenile animal data, adult and neonatal data and in vitro-in silico data (see ''Appendix'' for details). The different steps of the extrapolation approach are summarized in Fig. 1 .
2.1. In the first step (step 1, Sect. 6.1.1, ''Appendix''), we developed a population pharmacokinetic model, based on available data in neonates (94 fluconazole concentrations in 13 neonates). Given that this model refers to ''the reference model'' for all comparisons performed in step 5 (see below), the predictive performance of the developed model was further evaluated in an independent group of neonates (173 fluconazole concentrations from 12 neonates). The individual concentrations were predicted by Bayesian estimation (MAXEVAL = 0 in the estimation step, where MAXEVAL is the maximum number of model evaluations that can be used) with NONMEM using the population pharmacokinetic parameters.
2.2. In a second step (step 2, Sect. 6.1.2, ''Appendix''), we developed a population pharmacokinetic model based on juvenile animal data (60 fluconazole concentrations obtained by pooling the blood of 230 animals) and performed an extrapolation from juvenile mice to neonates.
2.3. In a third step (step 3, Sect. 6.1.3, ''Appendix''), we identified a population pharmacokinetic model based on adult data (180 concentrations in 12 adult volunteers) and performed extrapolation from adults to neonates.
2.4. In a fourth step (step 4, Sect. 6.1.4, ''Appendix''), we developed a physiologically based pharmacokinetic (PBPK) model of fluconazole and performed prediction to neonates.
2.5. During step 5 (Sect. 6.1.6, ''Appendix''), we used the models developed during steps 2 to 4 and extrapolation methods to predict fluconazole exposure (AUC) obtained at steady-steady with a standard loading-dose schedule in neonates. The predicted AUC was compared with reference AUC obtained in step 1. 
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The predictive performance was evaluated by calculating the prediction error (PE) using Eq. (1):
The PE was expressed as a percentage.
Results

Step 1. Reference Pharmacokinetic Parameters in Neonates
A one-compartment model with first order elimination was fitted to the neonatal pharmacokinetic data in the original dataset with 13 neonates. An exponential model best described inter-individual variability of clearance (CL) and volume of distribution (V d ). A proportional model best described residual variability. An analysis of covariates suggested that weight and gestational age had a significant impact on CL and only weight had a significant impact on V d . Model diagnostics showed an acceptable fit of the model to the data. As shown in Fig. 2a , b predictions were unbiased. In the diagnostic plots of conditional weighted residuals (CWRES) versus time and population predictions, no trends were observed (Fig. 2c, d ). In addition, the mean parameter estimates resulting from a bootstrap procedure (500 iterations) closely agreed with the respective values from the final population model, indicating that the estimates of the population pharmacokinetic parameters in the final model were accurate and that the model was stable (Table 2 ). The median values of estimated CL and V d in neonates were 0.016 L/h/kg and 1.03 L/kg, respectively. These values were the ''reference neonatal pharmacokinetic values'' used for the last step of comparison.
Step 2. Pharmacokinetic Model Juvenile Mice and Extrapolation to Neonates
A one-compartment model with first order elimination was fitted to the pharmacokinetic data from juvenile mice. An exponential model best described inter-individual variability of apparent CL. A proportional model best described residual variability. The covariates analysis identified that current weight and postnatal age had a significant impact on CL and only weight had a significant impact on V d . Table 2 presents the pharmacokinetic parameters of juvenile mice. The model was also validated by goodnessof-fit plots, bootstrap and NPDE ( Fig. 3a-f 3. Simple allometry with a corrected factor of maximum lifespan potential (MLP) for CL:
Individual Bayesian estimated CL was firstly multiplied by the mean MLP and then the results were plotted as a function of bodyweight on a log-log scale. The estimated coefficient and exponent using allometric equation (Eq. 5) were 1.2133 and 1.2932, respectively, After 100 simulations with these estimated parameters and a corrected factor of MLP, the median predicted neonatal CL was 0.016 L/h/kg.
The extrapolation approach using 0.91 L/kg for V d (weight normalized value of extrapolation method 1) and 0.016 L/h/kg for CL (allometry with corrected factor of MLP extrapolation method 3) gave the most consistent prediction of observed values (0.016 L/h/kg and 1.03 L/kg) in neonates (see bold values in Table 3 ). Figure 4a shows the correlation between individual predicted neonatal CL from juvenile mice and observed CL in neonates. Eighty-five percentages of (n = 11/13) patients were within 50 % prediction error.
Step 3. From Adults to Neonates
A one-compartment model with lag-time and first-order elimination was developed in adults [14] . We performed 100 simulations based on the reported pharmacokinetic parameters and extrapolation using the following three methods. (Table 3 ). Figure 4b shows the correlation between individual predicted neonatal CL from adults and observed CL in neonates. Seventy-seven percentages of (n = 10/13) patients were within 50 % prediction error. coefficient (logP) were obtained from the product monograph and published information [15, 16] . Parameters of the PBPK model were included as follows:
Step 4. From In Vitro-In Silico Data to Neonates
The blood and plasma concentrations of fluconazole being equivalents, the blood to plasma partition ratio (B/P) was set to 1 [15] . Fraction unbound in plasma (fu) has been reported as 0.89 [17] . In order to describe tissue distribution, a full PBPK distribution model was used with a fixed tissue/plasma partition coefficient of 10 in skin [15] . Data to define elimination was obtained from the pharmacokinetic study of intravenous fluconazole in adult healthy volunteers, where the total CL at steady state was 1.38 ± 0.24 L/h [18] . As the renal excretion is the major route of fluconazole elimination and the mean urinary recovery of unchanged fluconazole was 80 % [15] , fluconazole renal clearance (CL R ) was fixed to 1.1 L/h to account for 80 % of total systemic CL.
These parameters were entered in the Simcyp program ( Table 4 ). The median predicted CL and V d values for the 100 simulated clinical trials were 0.016 L/h/kg and 0.96 L/kg, respectively.
Step 5. Prediction of Fluconazole AUC
Using a ''loading dose regimen'' of 25 mg/kg followed by 12 mg/kg fluconazole daily over 2 h, the median predicted AUCs obtained at steady state, determined with the three models (step 2 juvenile mice, step 3 adults, and step 4 PBPK), were 766, 862 and 747 mgÁh/L, respectively (Table 5) . These values were in close agreement with the AUC of 783 mgÁh/L, calculated from neonatal population pharmacokinetic model (step 1). The PEs were -2.2, ?10.1 and -4.6 % for juvenile mice, adults and in vitro-in silico data, respectively.
Discussion
The dosage regimen used in the very first studies in neonates is often based on empirical scaling methods. The commonly used method for initial dosing selection in children is to normalize the adult dose by body weight or body surface area (i.e. mg/kg or mg/m 2 ), assuming a linear relationship between weight and/or surface area and dose [19] . Evaluation of these empirical methods has already shown that scaling based on body weight tend to underpredict drug CL in children and those based on body surface area frequently over-predict drug CL in young children. The prediction error is even more pronounced in neonates [20] . Therefore, there is an urgent need to improve selection of the first dose by developing and evaluating bridging studies based on the optimal use of available information before neonatal studies start. To try to reach this goal, we evaluated how pharmacokinetic bridging studies could be used to support dose selection to conduct drug evaluation for a neonatal indication. Our results highlight the important methodological aspects of applying the pharmacokinetic bridging approach in neonates, namely, the correction for inter-species differences, developmental physiological aspects (i.e. renal maturation) and the need to include prior pharmacokinetic information available in preclinical and adult studies. Taking these prerequisites into account, our results strongly support the use of all available sources of pharmacokinetic information to predict neonatal pharmacokinetics and initial dosage to be proposed for neonatal studies and/or recommended for therapeutic use.
It is currently stated that data from juvenile animals is better than data from adult animals to predict paediatric pharmacokinetics [21] . As this statement has never been validated, comparing juvenile and mature animals to predict the neonatal dose remains necessary. Previous research has shown that the inter-species pharmacokinetic extrapolation between mature i.e. mature animals and adults using the simple allometry without correction factor overestimated CL in humans [22] . In the present study, we have also shown that a bias exists in the extrapolation process from juvenile mice to neonates. The MLP factor (defined as the maximum observed life span of one species), was required to correct this bias. By including the correction MLP factor for CL and weight normalized V d , we demonstrate for the first time that population pharmacokinetics based extrapolation from juvenile mice to neonates, using allometry is possible. Indeed, with an identical dosage regimen, fluconazole exposure calculated with the juvenile animal model was close to neonatal predicted exposure obtained with a model derived from ''real neonatal data''. These data demonstrate good predictive performances of the juvenile animal model. In order to extrapolate pharmacokinetics from adults to paediatrics the fix-exponent allometric model (with exponents of 0.75 for CL and 1 for V d ), has been proposed, considering size as a major determinant reflecting maturation [23] . Although used for extrapolation from adults to adolescents and children with ''acceptable'' results, systematic biases were found in neonates and infants [20, 24] . This might reflect the continuous and rapid changes in pharmacokinetics that occur during the neonatal period as consequences of developmental changes affecting body composition, organ function and maturation of drug metabolic and excretion pathways. Our findings confirmed that fix-exponent allometric model alone over-predicted the CL in neonates. The age dependent exponent allometric model reduced prediction error and showed a reasonable accuracy (PE -39.4 %), however slightly under-predicted the CL of fluconazole in neonates. Indeed, age dependent exponent are based on the observation of a group of drugs. For each drug, the different maturation profile and developmental pharmacology should be taken into account. For fluconazole, it is known that renal maturation has an impact upon dose prediction in neonates [12] and this factor must be considered. We used the glomerular filtration rate (GFR) maturation model developed by Rhodin et al. [25] , based on a population metaanalysis of GFR (measured in 923 patients from very premature neonates to adults). The sigmoid hyperbolic model precisely describes the nonlinear relationship between GFR maturation and postmenstrual age after standardising size effect using allometric scaling [25] . Extrapolation based on adult population pharmacokinetic model incorporating the renal maturation model gave satisfactory drug exposure in neonates.
In vitro-in silico extrapolation to neonates was based on a PBPK model that offers a mechanistic approach to assess neonatal drug exposure. The PBPK approach establishes virtual populations by building up a mechanistic and physiological model, which incorporates known variabilities in demographic and biological parameters linked to drug-specific physico-chemical properties and data on drug ADME (absorption, distribution, metabolism and elimination) [26, 27] . The age-dependent changes in enzyme activities, blood flow, tissue size and composition (phospholipid, water and neutral lipid content) and their correlation with demographic factors (including weight, height and/or body surface area) were included in the Simcyp pediatric simulator [28] . A full PBPK distribution model to predict V d is based on parameters describing 14 key organs using a PBPK tissue/plasma partition coefficient model. For drugs that are extensively eliminated by the kidneys, maturation of clearance reflects maturation of the GFR and tubular function [29] [30] [31] . The renal maturation model in Simcyp was developed based on the changes of inulin, mannitol and 51 Cr-EDTA clearance with age. This renal maturation model has predicted vancomycin CL successfully in neonates [28] and similarly showed good prediction of fluconazole CL in neonates.
In order to confirm that the dosage prediction was possible by using at least one of the proposed strategies, a loading dose treatment schedule was tested in the three models and compared to the ''real neonatal model'' developed from data obtained in neonates receiving fluconazole. The PEs varied from -4.6 to 10.1 %, indicating a good predictive performance of model-based extrapolations from juvenile mice, adults and in vitro-in silico data.
Some limitations should be underlined. As a proof-ofconcept study, our positive results are obtained with a PBPK physiologically based pharmacokinetic, LogP octanol-water partition coefficient, pKa acid dissociation constant, B/P ratio blood to plasma concentration ratio, fu unbound fraction, CL R renal clearance 
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First Dose in Neonatesrenally eliminated drug, for which the developmental changes have been extensively studied in neonates. The separate contribution of developmental changes of glomerular filtration, tubular secretion and reabsorption on the renal maturation should be further evaluated across the pediatric age range. A thorough understanding of maturation profile of each pathway can increase the precision in the prediction. The bridging approach should be also proposed for other drugs, including highly metabolised drugs, although modeling developmental metabolic processes will likely be much more complex than modeling renal maturation changes, as data of ontogeny of drug metabolism and transport are still limited. The present study gave consistent predictions of neonatal pharmacokinetics from different sources. We cannot arbitrarily decide which approach is better than others. Given the complexities in the prediction of first dose in neonate, we suggest an optimal use of all available sources. The final decision should also consider the safety of evaluated drugs and prior knowledge of developmental pharmacokinetics-pharmacodynamics in neonates.
Conclusion
We conducted a proof-of-concept study with fluconazole as a model drug, to predict drug dosage in neonates from juvenile mice, adults and in vitro-in silico data using model-based pharmacokinetic bridging approaches. Our results firstly support the feasibility of pharmacokinetic bridging approach in neonates, which can be used in drug development to predict the first neonatal dose before conducting a population pharmacokinetic study and clinical trials in neonates. Such bridging approaches should be further tested and validated, as it remains the only way to select the first dose in neonates using a scientific ''evidence based'' approach. Author contributions Zhao W and Jacqz-Aigrain E designed the research. Benjamin DK Jr., Watt KM, Saxen H and Hoppu K provided pharmacokinetic data in neonates. Matrot B and Bourgeois T provided pharmacokinetic data in juvenile mice. Zhao W performed data analysis. Le Guellec C, Hope WW, van den Anker JN, Benjamin DK Jr., Manzoni P and Jacqz-Aigrain E contributed to the discussion and interpretation of the results. Zhao W wrote the manuscript, which was critically reviewed by all authors.
Appendix
Methods
We derived the population pharmacokinetic models from juvenile mice and adult healthy volunteers, and PBPK model from in vitro-in silico data to predict fluconazole dose in neonates.
Population Pharmacokinetic Parameters in Neonates
The data used to develop the population pharmacokinetic model was obtained from a prospective, single-center, open-label pharmacokinetic trial at Duke University Medical Center in Durham, NC. Thirteen neonates and young infants were given an intravenous loading dose (25 mg/kg administered over 2 h via a syringe pump) followed by maintenance therapy (12 mg/kg/day over 1 h every 24 h). Blood samples were taken at the following time points after the end of the infusion: 0-30 min, 2-4 h, 6-12 h, and 18-24 h after the first dose and peak and trough samples at doses 3 and 5 [32] . A summary of study characteristics and the demographic variables is provided in Table 1 . A total of 94 fluconazole concentrations ranging from 6.9 to 47.2 lg/mL were available. The population pharmacokinetic analysis was carried out using the nonlinear mixed effects modeling program NONMEM V 7.2 (Icon Development Solutions, Ellicot City, MD, USA). We used first order conditional estimation (FOCE) method with interaction option to estimate pharmacokinetic parameters and their variability. We estimated inter-individual variability of the pharmacokinetic parameters using an exponential model, which was expressed by Eq. (2):
where h i represents the parameter value of the ith subject, h mean the typical value of the parameter in the population and gi the variability between subjects which is assumed to follow a normal distribution with a mean of zero and variance x 2 . Covariate analysis followed a forward and backward selection process. We used stepwise covariate modelling [33] and likelihood ratio test to evaluate the effect of each variable. During the first step of covariate model building, a covariate was included if a significant (p \ 0.05, v 2 distribution with one degree of freedom) decrease (reduction [3.84) in the objective function value (OFV) from the basic model was obtained. All the significant covariates were then added simultaneously into a 'full' model. Subsequently each covariate was independently removed from the full model. If the increase in the OFV was lower than 6.635 (p \ 0.01, v 2 distribution), the covariate was considered significantly correlated to the pharmacokinetic parameter and was therefore included in the final model.
Model validation was based on graphical and statistical criteria. Goodness-of-fit plots, including observed concentration versus individual prediction, observed concentration versus population prediction (PRED), conditional weighted residuals (CWRES) versus time and CWRES versus PRED were used initially for diagnostic purposes [34] . The stability and performance of the final model were also assessed by means of a nonparametric bootstrap with re-sampling and replacement. Re-sampling was repeated 500 times and the values of estimated parameters from the bootstrap procedure were compared with those estimated from the original data set. The entire procedure was performed in an automated fashion, using PsN (v2.30) [35] . The final model was also evaluated graphically and statistically by normalized prediction distribution errors (NPDE) [36] . 1,000 datasets were simulated using the final population model parameters. NPDE results were summarised graphically by default as provided by the NPDE R package (v1.2) [37] : (i) QQ-plot of the NPDE; (ii) histogram of the NPDE. The NPDE is expected to follow the N (0, 1) distribution.
The predictive performance of the developed model was further evaluated in an independent group of neonates. The data was obtained from a prospective, single-center, openlabel pharmacokinetic trial at the neonatal intensive care unit of Hospital for Children and Adolescents, University of Helsinki. Twelve preterm neonates were given fluconazole (6 mg/kg administered over 15 min via an infusion pump every 72 h) for prophylaxis therapy. Blood samples were collected before and at the end of the infusion, as well as at 3, 6, 24, 48 , and 72 h after the first infusion was started. The same sampling was repeated after the third and fifth doses [38] .
From Juvenile Mice to Neonates
The pharmacokinetic data in juvenile mice (Swiss strain) was obtained from an open-label, repeated-doses pharmacokinetic study within the FP7 TINN project (Treatment Infection in NeoNates). The mice were born at 19 days gestation age. Two dosing regimens 6 or 60 mg/kg once daily were given subcutaneously since postnatal day 2 (Table 1) . Pharmacokinetic samplings were obtained at times of T0.5 h or T23 h on day 1, T23 h on day 5, T23 h on day 10, or T0.5 h or T23 h on day 11. Population pharmacokinetic analysis was carried out using NONMEM. Modeling and validation processes were similar to neonates, as described above.
We used the following extrapolation approaches to predict pharmacokinetic parameters in neonates from juvenile mice [22, 39- 
Maximum lifespan potential (MLP) is an estimate of the maximum amount of time that a member of a given species could survive. It has been used to correct the prediction bias of interspecies scaling from animal to human [39] . In this approach, the individual Bayesian estimated CL in mice was multiplied by its MLP value and were plotted as a function of bodyweight on a log-log scale. The coefficient and exponent (d and e in the equation) were estimated from the allometric equation. The MLP was calculated by the equation as described by Sacher [42] . Brain weight values are 120 mg on day 1, 248 mg on day 5 and 314 mg on day 11 [43] , whereas 81,8000 h is the MLP in humans. 
where Vd NN is the predicted Vd in neonates, WT NN is the bodyweight in neonates; f is the estimated weight normalized Vd in juvenile mice. Although the bioavailability (F) of fluconazole is unknown in juvenile mice whatever the route of administration, ''reference values'' do exist showing that fluconazole is almost completely absorbed both in animals and humans: F was 108 % in sea turtles after subcutaneous administration, [90 % in human and 109 % in cats after oral administration [44, 45] . Thus, we assumed a value of 100 % for F after sub-cutaneous administration in juvenile mice and oral administration in human.
From Adult Health Volunteers to Neonates
The pharmacokinetic data in adult healthy volunteers was identified from literature [46] . In a phase 1 study, 12 healthy male volunteers received a single oral dose of fluconazole 100 mg. An average of 15 blood samples per patient was taken between 5 min and 168 h postdose. A one-compartment population pharmacokinetic model was developed based on data from this pharmacokinetic study [14] , which was used in the present study.
We used the following extrapolation approach to predict pharmacokinetics in neonates from adult healthy volunteers [23, 25, 47 where exp_age is age dependent exponent: 1.2 for children B3 months and 1.0 for children [3 months to 1 year.
From In Vitro-In Silico Data to Neonates
The PBPK model was carried out using the software Simcyp version 12 release 1 (Simcyp Limited, Sheffield, UK). Drug data (e.g., drug molecular weight, physicochemical characteristics such as logP (octanol-water partition coefficient) and pKa, drug elimination etc.) was obtained from the literature. The Systems data in children (e.g. physiology, anatomy, biology, and biochemistry defined based on pediatric population demographics) was set to default values, as described by Johnson et al [28] .
Extrapolation approach
The default kidney maturation model in Simcyp [Eq. (14) ] was used for extrapolation [28] : Glomerular filtration rate (mL/minÞ ¼ ðÀ6:1604 Â Body surface area 2 Þ þ ð99:054 Â Body surface areaÞ À 17:74 ð14Þ
Evaluation of Model-Based Extrapolations
Given our interest in dosage prediction using model-based approaches, we tested the performance of the proposed approaches via simulation. We extensively evaluated whether the two population pharmacokinetic models derived from juvenile mice and adults, and the PBPK model derived from in vitro-in silico data with associated extrapolation approaches could be used to accurately predict observed pharmacokinetic parameters in neonates. We elected CL and V d as endpoints for the purpose of this evaluation and performed 100 simulations using NON-MEM and Simcyp, respectively.
Predictive Performance of the Model in Dosage Prediction
Fluconazole pharmacokinetic-pharmacodynamic relationship was best described by using the ratio of area under curve and minimal inhibition concentration (AUC/MIC). The selection of pediatric dose is based on the target exposure (AUC 0-24 ) of 800 mgÁh/L, reported in adult intensive care patients or immunocompromised patients treated with fluconazole at 800 mg/day. This AUC target ensures that exposure exceeds the AUC/MIC pharmacodynamic target of 50 h for Candida species with a MIC of 8 mg/L [12, 48, 49] .
In the next step, we tested different simulation scenarios to evaluate whether model-based extrapolation could be used to accurately predict drug exposure and support the dosage prediction in neonates. The loading dose regimen previously recommended for neonates [32] , consisting of a loading dose of 25 mg/kg (intravenous infusion over 2 h) followed by maintenance doses of 12 mg/kg (intravenous infusion over 1 h) was used to perform 100 simulations using our models previously developed: population pharmacokinetic models in mice and adults, PBPK model and population pharmacokinetic model in neonates to calculate predicted and reference AUCs, respectively.
